PubMed · 2012 · 13 citations · 29 references
MedicineOncologyRadiation OncologyChemotherapyMedical OncologyPediatric OncologyCytotoxic ChemotherapyHigh-dose ChemotherapyPediatric Central Nervous System RadiotherapyPediatric ChemotherapyRadiation TherapyChemotherapy Dose IntensityChemotherapy-related ToxicityManagement Of High-risk PatientsMedulloblastoma ChemotherapyMedulloblastoma Radiotherapy
AIM: To determine the relationship between prescribed dose-intensity of chemotherapy and survival in childhood medulloblastoma. MATERIALS AND METHODS: A total of 55 trials from 1970-2009 were identified, 30 were eligible for analysis, with individual treatment regimes with 5-year (or more) outcome figures. Relationships of outcome to dose-intensity were analysed using weighted regression. RESULTS: Overall, 2,434 patients were identified, 1,010 were classified as 'standard'- and 671 as 'high'-risk patients, with 5-year overall survivals (OS) of 67.2% (95% Confidence Interval=60.5%-73.6%) and 47.6% (95% Confidence Interval=39.5%-55.7%), respectively. A protective effect for chemotherapy versus craniospinal radiotherapy alone (5-year OS of 58.2% versus 51.6%) was found. Individually, vincristine, cisplatin, lomustine (CCNU) and cyclophosphamide appear to confer the most beneficial effect, particularly for high-risk patients. Positive relationships between OS and dose-intensity were found, except for lomustine, with cyclophosphamide offering the greatest protection. CONCLUSION: Consideration of chemotherapy dose-intensity may further optimise treatment, particularly in the context of risk stratification.
29
Amar Gajjar, Murali Chintagumpala, David M. Ashley et al. · The Lancet Oncology · 2006 · 949 citations · Full text
Medicine, Oncology, Pediatrics +17
Paul M. Zeltzer, James M. Boyett, Jonathan L. Finlay et al. · Journal of Clinical Oncology · 1999 · 756 citations
Medicine, Oncology, Pediatrics +17